Production and use of novel peptide-based agents for use with bi-specific antibodies
AssigneeImmunomedics, Inc.
InventorsHans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
Life of this patent
Estimating the term…
Abstract
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
Claims30
A method of treating or identifying diseased tissues in a subject, comprising:
- (A) administering to said subject a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate comprising at least two HSG haptens,
- wherein said at least one other arm that specifically binds a targetable conjugate comprising at least two HSG haptens comprises the Fv of mAb 679;
- (B) optionally, administering to said subject a clearing composition, and allowing said composition to clear non-localized antibodies or antibody fragments from circulation;
- (C) administering to said subject a targetable conjugate which comprises a carrier portion which comprises or bears at least two HSG haptens and may comprise a diagnostic or therapeutic cation, and/or one or more chelated or chemically bound therapeutic or diagnostic agents, or enzymes;
- and
- (D) when said targetable conjugate comprises an enzyme, further administering to said subject
- 1) a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site;
- or
- 2) a drug which is capable of being detoxified in said subject to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or
- 3) a prodrug which is activated in said subject through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site.
Dependencies are inferred from the claim text.